January 2025 Targeted Pulse

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on treatment choices for gastric adenocarcinoma and ctDNA monitoring and clearing in HER2-positive breast cancer.

In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC research in NSCLC, and potential future FDA approvals under consideration.

Nivolumab demonstrated superior efficacy in LA-HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib showed OS improvement in NSCLC, and sunvozertinib has been granted priority review status for NSCLC.